BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Papageorgiou N, Zacharia E, Briasoulis A, Charakida M, Tousoulis D. Celecoxib for the treatment of atherosclerosis. Expert Opinion on Investigational Drugs 2016;25:619-33. [DOI: 10.1517/13543784.2016.1161756] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Kumar JSD, Zanderigo F, Prabhakaran J, Rubin-Falcone H, Parsey RV, Mann JJ. In vivo evaluation of [11C]TMI, a COX-2 selective PET tracer, in baboons. Bioorg Med Chem Lett 2018;28:3592-5. [PMID: 30396759 DOI: 10.1016/j.bmcl.2018.10.049] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
2 Li L, Li J, Yi J, Liu H, Lei H. Dose-Effect of Irbesartan on Cyclooxygenase-2 and Matrix Metalloproteinase-9 Expression in Rabbit Atherosclerosis. J Cardiovasc Pharmacol 2018;71:82-94. [PMID: 29420356 DOI: 10.1097/FJC.0000000000000544] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
3 Song K, Li L, Sun G, Wei Y. MicroRNA-381 regulates the occurrence and immune responses of coronary atherosclerosis via cyclooxygenase-2. Exp Ther Med 2018;15:4557-63. [PMID: 29725388 DOI: 10.3892/etm.2018.5947] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Zhang R, Hao Y, Zhang J. The lncRNA DANCR promotes development of atherosclerosis by regulating the miR-214-5p/COX20 signaling pathway. Cell Mol Biol Lett 2022;27:15. [PMID: 35177003 DOI: 10.1186/s11658-022-00310-2] [Reference Citation Analysis]
5 Prabhakaran J, Underwood M, Zanderigo F, Simpson NR, Cooper AR, Matthew J, Rubin-Falcone H, Parsey RV, Mann JJ, Dileep Kumar JS. Radiosynthesis and in vivo evaluation of [11C]MOV as a PET imaging agent for COX-2. Bioorg Med Chem Lett 2018;28:2432-5. [PMID: 29929881 DOI: 10.1016/j.bmcl.2018.06.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
6 Simon MS, Burger B, Weidinger E, Arteaga-Henríquez G, Zill P, Musil R, Drexhage HA, Müller N. Efficacy of Sertraline Plus Placebo or Add-On Celecoxib in Major Depressive Disorder: Macrophage Migration Inhibitory Factor as a Promising Biomarker for Remission After Sertraline-Results From a Randomized Controlled Clinical Trial. Front Psychiatry 2021;12:615261. [PMID: 34646168 DOI: 10.3389/fpsyt.2021.615261] [Reference Citation Analysis]
7 Kusters PJH, Lutgens E, Seijkens TTP. Exploring immune checkpoints as potential therapeutic targets in atherosclerosis. Cardiovasc Res 2018;114:368-77. [PMID: 29309533 DOI: 10.1093/cvr/cvx248] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 12.3] [Reference Citation Analysis]
8 Kumar JSD, Bai B, Zanderigo F, DeLorenzo C, Prabhakaran J, Parsey RV, Mann JJ. In Vivo Brain Imaging, Biodistribution, and Radiation Dosimetry Estimation of [11C]Celecoxib, a COX-2 PET Ligand, in Nonhuman Primates. Molecules 2018;23:E1929. [PMID: 30072617 DOI: 10.3390/molecules23081929] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
9 Zheng X, Wen J, Liu TH, Ou-Yang QG, Cai JP, Zhou HY. Genistein Exposure Interferes with Pharmacokinetics of Celecoxib in SD Male Rats by UPLC-MS/MS. Biochem Res Int 2017;2017:6510232. [PMID: 29387488 DOI: 10.1155/2017/6510232] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Li J, Wang W, Han L, Feng M, Lu H, Yang L, Hu X, Shi S, Jiang S, Wang Q, Ye L. Human apolipoprotein A-I exerts a prophylactic effect on high-fat diet-induced atherosclerosis via inflammation inhibition in a rabbit model. Acta Biochim Biophys Sin (Shanghai) 2017;49:149-58. [PMID: 28069582 DOI: 10.1093/abbs/gmw128] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
11 Tome T, Časar Z, Obreza A. Development of a Unified Reversed-Phase HPLC Method for Efficient Determination of EP and USP Process-Related Impurities in Celecoxib Using Analytical Quality by Design Principles. Molecules 2020;25:E809. [PMID: 32069880 DOI: 10.3390/molecules25040809] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]